Insider Buying: Marker Therapeutics, Inc. (NASDAQ:MRKR) Director Acquires 11,085 Shares of Stock

Marker Therapeutics, Inc. (NASDAQ:MRKR) Director Steve Elms bought 11,085 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the acquisition, the director now owns 325,370 shares in the company, valued at $1,041,184. This represents a 3.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Marker Therapeutics Stock Up 3.6 %

Shares of NASDAQ MRKR opened at $3.49 on Friday. Marker Therapeutics, Inc. has a fifty-two week low of $2.44 and a fifty-two week high of $6.16. The firm’s 50-day simple moving average is $3.72 and its 200 day simple moving average is $3.83.

Institutional Trading of Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. boosted its stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned approximately 0.78% of Marker Therapeutics worth $377,000 as of its most recent SEC filing. Institutional investors own 22.39% of the company’s stock.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH upped their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a report on Monday, October 21st.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.